TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26031764

Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg/day)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 5% Minoxidil
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Combined medication (Finasteride + 5% Minoxidil)
Number of subjects: 450
Study: 24268976

Group type: EXPERIMENTAL
Intervention: High flexion prosthesis
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard prosthesis
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 278
Study: 23057323

Group type: EXPERIMENTAL
Intervention: High dose beta-conglycinin (4.6g in 8 test tablets daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low dose beta-conglycinin (2.3g in 4 test tablets daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (4 tablets containing no beta-conglycinin)
Number of subjects: 100
Study: 19197821

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG) alone
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Combined Hysterosalpingography (HSG) and Sonohysterography (SHG)
Number of subjects: 208
Study: 17698897

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE therapy)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15774788

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 weekly for 9 cycles)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2 every 2 weeks for 4 cycles)
Number of subjects: 54
Study: 12361192

Group type: EXPERIMENTAL
Intervention: ACEI + NAC (600 mg t.i.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: ACEI only
Number of subjects: 18
Study: 9825365

Group type: EXPERIMENTAL
Intervention: Onset of AF episodes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mid-portion of AF episodes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Termination of AF episodes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Onset to mid-portion comparison
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mid-portion to termination comparison
Number of subjects: 25
Study: 8303575

Group type: EXPERIMENTAL
Intervention: Twice daily fractionation schedules of 1.2 Gy/fraction, 1.4 Gy/fraction, and 1.6 Gy/fraction with an interfraction interval of four to six hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TDFt and TSD concepts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LQ concept
Number of subjects: 0
Study: 2640159

Group type: EXPERIMENTAL
Intervention: Focused attention condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided attention condition
Number of subjects: 0
Study: 6995617

Group type: EXPERIMENTAL
Intervention: SRELAX (Transcendental Meditation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NSRELAX (Placebo control, identical training without a mantra)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 41
Study: 30409443

Group type: EXPERIMENTAL
Intervention: MV-CHIK (5×10^4 or 5×10^5 50% tissue culture infectious dose)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 263
Study: 27889312

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 888

Group type: COMPARATOR
Intervention: Carbamazepine-CR
Number of subjects: 888
Study: 26475016

Group type: EXPERIMENTAL
Intervention: Healthy Beginning Initiative (intervention group)
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Standard health facility referral (control group)
Number of subjects: 3002
Study: 23646470

Group type: EXPERIMENTAL
Intervention: Yiqi Qushi Recipe (YQR), one dose daily for eight weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pyridostigmine 60 mg, three times a day for eight weeks
Number of subjects: 40
Study: 21280171

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) and glycemic load (GL) diets
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control diets (not specified)
Number of subjects: 23
Study: 19736635

Group type: EXPERIMENTAL
Intervention: Continuation of warfarin therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Discontinuation of warfarin therapy
Number of subjects: 168
Study: 17844693

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antisnake venom (ASV) and other routine measures (Control group)
Number of subjects: 80
Study: 16354711

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15-30 mg elemental zinc daily for 14 days)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 14614169

Group type: EXPERIMENTAL
Intervention: Caregiving during the year before the patient's death
Number of subjects: 217
Study: 10709819

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Tranexamic acid (TXA) 10 g over 20 minutes before sternotomy
Number of subjects: 56
Study: 8755849

Group type: EXPERIMENTAL
Intervention: Zinc parameters (ZnE, ZnS, ZuU)
Number of subjects: 31
Study: 1928856

Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl 3 micrograms.kg‐1.h‐1 (Group I)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous infusion of fentanyl 1 microgram.kg‐1.h‐1 and enflurane 1.2 +/‐ 0.3 vol % (Group II)
Number of subjects: 12
Study: 6811475

Group type: EXPERIMENTAL
Intervention: High-ascorbate; average survival 246 days (55 patients)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High-ascorbate; average survival 1550 days (3 patients still alive)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High-ascorbate; average survival 115 days (6 patients)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control; average survival 48 days (19 patients)
Number of subjects: 130
Study: 31813632

Group type: EXPERIMENTAL
Intervention: Soap and water
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Disposable wet wipes
Number of subjects: 58
Study: 29890377

Group type: EXPERIMENTAL
Intervention: SDI-T
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SDI-T + AL
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SDI-T + D
Number of subjects: 64
Study: 26962727

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: mefloquine-artesunate
Number of subjects: 3428
Study: 24033611

Group type: COMPARATOR
Intervention: Two-step strategy (INT2)
Number of subjects: 39

Group type: COMPARATOR
Intervention: One-step strategy (INT1)
Number of subjects: 39
Study: 22048929

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard hospital practice (Control)
Number of subjects: 81
Study: 20455619

Group type: EXPERIMENTAL
Intervention: Quitline telephone counseling for smoking cessation; details on dosage and duration not available.
Number of subjects: 0
Study: 18195316

Group type: EXPERIMENTAL
Intervention: Vital sign intervention (documenting smoking status as a routine vital sign)
Number of subjects: 6729

Group type: COMPARATOR
Intervention: Control practices (no systematic tobacco screening or identification system)
Number of subjects: 6729

Group type: EXPERIMENTAL
Intervention: Vital sign intervention
Number of subjects: 6729

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 6729
Study: 12440177

Group type: EXPERIMENTAL
Intervention: forced diuresis with i.v. crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure was < 20 mmHg), and low dose dopamine
Number of subjects: 98

Group type: COMPARATOR
Intervention: intravenous crystalloid and matching placebos
Number of subjects: 98
Study: 10338174

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 16
Study: 7573992

Group type: EXPERIMENTAL
Intervention: Computer-controlled infusion of alfentanil (CCiA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patient-controlled administration of morphine (PCAM)
Number of subjects: 20
Study: 1938446

Group type: EXPERIMENTAL
Intervention: Urethral catheter
Number of subjects: 75

Group type: COMPARATOR
Intervention: Suprapubic catheter
Number of subjects: 75
Study: 7128131

Group type: EXPERIMENTAL
Intervention: Progestogens combined with ethinyl estradiol (EE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized dose of ethinyl estradiol
Number of subjects: 0
Study: 30474401

Group type: EXPERIMENTAL
Intervention: Lifelike baby doll intervention (three, 30-minute, individual, non-facilitated sessions per week)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lifelike baby doll intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study: 28625806

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25875387

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23837673

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Employment status, post test verbal memory performance, executive functioning measures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allocation to treatment group
Number of subjects: 60
Study: 21034687

Group type: EXPERIMENTAL
Intervention: Cognitive therapy + risperidone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Cognitive therapy + placebo
Number of subjects: 115

Group type: COMPARATOR
Intervention: Supportive therapy + placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: All groups (cognitive therapy + risperidone, cognitive therapy + placebo, supportive therapy + placebo)
Number of subjects: 115
Study: 19125906

Group type: EXPERIMENTAL
Intervention: Paroxetine CR (12.5-50 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 72
Study: 17300798

Group type: EXPERIMENTAL
Intervention: Assessment of goal neglect in preschool children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimensional Change Card Sort (DCCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opposite color response inhibition task
Number of subjects: 0
Study: 14517708

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg daily for 6 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11063909

Group type: EXPERIMENTAL
Intervention: Alpha-tocotrienyl acetate (250 mg/d)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gamma-tocotrienyl acetate (250 mg/d)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Delta-tocotrienyl acetate (250 mg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8817801

Group type: EXPERIMENTAL
Intervention: treatment A
Number of subjects: 0

Group type: COMPARATOR
Intervention: treatment B
Number of subjects: 0
Study: 1433686

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE, 15 mg)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE, 1 mg)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: High-dose norepinephrine (NE, 11 mg)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category score for HDE
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category score for NE
Number of subjects: 816

Group type: COMPARATOR
Intervention: Cerebral Performance Category score for SDE
Number of subjects: 816
Study: 3001605

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide
Number of subjects: 20
Study: 31698361

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin plus aspirin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Urinary PlGF concentrations at mid-pregnancy
Number of subjects: 187
Study: 28832630

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5ug twice daily (group II)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9ug twice daily (group III)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5ug twice daily with tiotropium 18ug once daily (group IV)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Tiotropium 18ug once daily (group I)
Number of subjects: 324
Study: 25879343

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,000 mg/m² daily) and oxaliplatin (85 mg/m² IV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5-FU (350 mg/m²) and leucovorin (20 mg/m²)
Number of subjects: 42
Study: 23290547

Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 μg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21088675

Group type: EXPERIMENTAL
Intervention: Lipid-heparin infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 19720764

Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring device
Number of subjects: 591

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 591
Study: 17868864

Group type: EXPERIMENTAL
Intervention: Current treatment modalities for myeloproliferative HES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current treatment modalities for idiopathic HES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current treatment modalities for lymphocytic‐variant HES
Number of subjects: 0
Study: 15521004

Group type: EXPERIMENTAL
Intervention: BILN 2061 500 mg twice daily for 2 days
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BILN 2061 200 mg twice daily for 2 days
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BILN 2061 25 mg twice daily for 2 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11161394

Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m² at day 1-3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study: 9788689

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Budesonide (topical steroid treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Levocabastine (topical antihistamine)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SCF (Stem Cell Factor) presence in nasal lavage fluids
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Polyclonal antibody against SCF
Number of subjects: 29
Study: 7633557

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide (250 micrograms)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nebulised saline (placebo)
Number of subjects: 66
Study: 2791180

Group type: EXPERIMENTAL
Intervention: 10 mg IV prochlorperazine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 321183

Group type: EXPERIMENTAL
Intervention: sulindac 200 mg twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: aspirin 3.6 g daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: aspirin
Number of subjects: 31
Study: 31900997

Group type: EXPERIMENTAL
Intervention: Inhaled verapamil (10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (4 cc nebulized distilled water)
Number of subjects: 20
Study: 31117986

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study: 29057836

Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CM) 6 g
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study: 26150574

Group type: EXPERIMENTAL
Intervention: Heat training in 38°C (T38)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Heat training in 18°C (T18)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Blood volume expansion with albumin solution in 38°C (T38A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heat training effects on plasma volume
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heat training effects on mean sweat output
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heat training effects on sweat [Na(+)]
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heat training effects on MCAvmean
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Q̇max before and after training in 38°C
Number of subjects: 7
Study: 23782502

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Sitagliptin + Pioglitazone
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 21726984

Group type: EXPERIMENTAL
Intervention: Bolus injection of 1g every 8 h (q8h) for 24 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3‐h infusion of 1 g q8h for 24 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3‐h infusion of 2 g q8h for 24 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All three regimens of meropenem
Number of subjects: 8
Study: 19292653

Group type: EXPERIMENTAL
Intervention: Auricular acupressure by seed-pressure method
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (plain adhesive patch)
Number of subjects: 71
Study: 17006839

Group type: EXPERIMENTAL
Intervention: 60 mCi of (131)I
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 100 mCi of (131)I
Number of subjects: 224
Study: 12680181

Group type: COMPARATOR
Intervention: Cyclophosphamide 500 mg/m2 on days 1 and 2 plus epidoxorubicin 90 mg/m2 on day 1 every 3 weeks (group A)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2/cycle plus doxorubicin 50 mg/m2/cycle every 3 weeks (group B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2/cycle plus epidoxorubicin 90 mg/m2/cycle every 21 days (group C)
Number of subjects: 58
Study: 10587129

Group type: EXPERIMENTAL
Intervention: Portal venous-dominant phase CT
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hepatic arterial-dominant phase CT
Number of subjects: 300

Group type: COMPARATOR
Intervention: Unenhanced images
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall lesion detection
Number of subjects: 300
Study: 9085509

Group type: EXPERIMENTAL
Intervention: Sound-induced autonomic arousals
Number of subjects: 63

Group type: COMPARATOR
Intervention: Current definitions of arousals
Number of subjects: 63
Study: 1676891

Group type: EXPERIMENTAL
Intervention: 20 mEq/day NaCl diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: 200 mEq/day NaCl diet
Number of subjects: 27
Study: 6756530

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study: 4054064

Group type: EXPERIMENTAL
Intervention: Intracervical application of 0.1 mg Sulprostone‐Tylose gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment with local prostaglandin)
Number of subjects: 10
Study: 31765659

Group type: EXPERIMENTAL
Intervention: 250 μm of androstadienone (AND)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo odor
Number of subjects: 52
Study: 30076108

Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy boost with 23 fractions of IMRT and 2 fractions of brachytherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT) alone with 44 fractions
Number of subjects: 0
Study: 25845835

Group type: EXPERIMENTAL
Intervention: Potentially reduced exposure tobacco products
Number of subjects: 136
Study: 24999282

Group type: EXPERIMENTAL
Intervention: Antivenom
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 22552183

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Control group (pharmacological therapy)
Number of subjects: 813
Study: 20167900

Group type: EXPERIMENTAL
Intervention: Tailored materials including personalized risk feedback
Number of subjects: 596

Group type: COMPARATOR
Intervention: General educational materials
Number of subjects: 596
Study: 18541356

Group type: EXPERIMENTAL
Intervention: Late-night sleep (rich in REM sleep)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early-night sleep (rich in SWS)
Number of subjects: 0
Study: 15793381

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 57

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 57
Study: 12641687

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% 1 ml.kg(‐1) (group B, n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% 1 ml.kg(‐1) and preservative‐free s‐ketamine 0.5 mg.kg(‐1) (group K, n = 15)
Number of subjects: 30
Study: 10682152

Group type: COMPARATOR
Intervention: Zidovudine (200 mg three times daily) plus Lamivudine (300 mg twice daily)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg three times daily) plus Lamivudine (300 mg twice daily) plus Loviride (100 mg three times daily)
Number of subjects: 106
Study: 8917255

Group type: EXPERIMENTAL
Intervention: Reviparin (7,000 U bolus before PTCA, followed by 10,500 U infusion over 24 h, then 3,500 U subcutaneous application twice daily for 28 days)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control (10,000 U unfractionated heparin bolus followed by 24,000 U infusion over 24 h, then subcutaneous placebo injections for 28 days)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control
Number of subjects: 625
Study: 1888046

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) 15 micrograms.kg‐1
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS)
Number of subjects: 22